C4 Therapeutics (CCCC) Cash from Investing Activities (2019 - 2026)

C4 Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 44.54% year-over-year to $16.2 million in Q1 2026; TTM through Mar 2026 was -$21.6 million, a 169.03% decrease from a year earlier, with the FY2025 full-year figure at -$8.6 million, up 83.22% from the prior year.
• Cash from Investing Activities grew to $16.2 million in Q1 2026 per CCCC's latest filing, from -$80.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $57.7 million in Q3 2023 and bottomed at -$80.7 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $15.1 million (2023), against an average of $10.2 million.
• Biggest YoY gain for Cash from Investing Activities was 2422.22% in 2025; the steepest drop was 690.59% in 2025.
• Year by year, Cash from Investing Activities stood at $9.3 million in 2022, then jumped by 244.09% to $31.9 million in 2023, then plunged by 57.21% to $13.7 million in 2024, then sank by 690.59% to -$80.7 million in 2025, then jumped by 120.01% to $16.2 million in 2026.
• Per Business Quant, the three latest CCCC Cash from Investing Activities figures stand at $16.2 million (Q1 2026), -$80.7 million (Q4 2025), and $4.1 million (Q3 2025).